Navigation Links
Helix BioPharma Announces Q1 2009 Financial Results
Date:12/11/2008

64 66 Amortization of intangibles 3 7 Stock-based compensation - 12 Foreign exchange loss 150 108 (2,104) (1,451) Change in non-cash working capital 486 (192) Operating activities (1,618) (1,643) Financing activities 9,659 - Investing activities (37) (50) Effect of exchange rate changes on cash and cash equivalents (150) (108) Increase in cash and cash equivalents 7,854 (1,801) Cash and cash equivalents: Beginning of the period 19,057 11,379 End of the period 26,911 9,578

    Consolidated Balance Sheets as at
     ($ thousands)
                                             31-Oct      31-Jul
                                               2008       2008
       Current assets:
        Cash and cash
         equivalents                         26,911      19,057
        Accounts receivable                     500         349
        Inventory                               521         458
        Prepaid and other                       222         446
        Deferred financing
         costs                                    -           -
                                             28,154      20,310

       Non current assets                     1,266       1,356

                                             29,420      21,666



                                             31-Oct      31-Jul
                                              2008        2008
     Current liabilities:
      Accounts payable                         
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... announced today that it intends to begin manufacturing in ... approximately 106,000,square feet in the Binjiang Hi-Tech Park located ... serve global customers with regional,decision centers in the greater ... lowest total cost value proposition. This location,will be the ...
... in the filter industry? Are you an investment analyst ... a filter company looking to gain an edge in ... filter and filtration markets. On September 23-25, 2008 at ... American Filtration and Separations Society (AFS) will be holding ...
... they recently discovered a catalyst that produces oxygen gas ... $20 million award from the National Science Foundation (NSF), ... (CBC) project, called "Powering the Planet," will increase the ... efficiently and economically converting solar energy and water into ...
Cached Biology Technology:Plexus Announces Expansion in Hangzhou, China 2Plexus Announces Expansion in Hangzhou, China 3Filter Markets - Discover the Growth Segments 2Filter Markets - Discover the Growth Segments 3Understanding the science of solar-based energy: more researchers are better than one 2
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
(Date:12/3/2014)... , Dec. 2, 2014   Marvin Test ... innovative test solutions for military, aerospace, and manufacturing ... of its successful TS-900 PXI semiconductor test ... features of high-end systems to customers at a ... compared to traditional ATE. "Our ...
(Date:11/21/2014)... 18, 2014 According to a ... Systems (Video, RFID, Access Control, Intrusion Detection, Parking Management, ... Government), Component Service Geography - Global Forecasts to 2020", ... projected to be around $25 Billion in 2014 and ... at a CAGR of 8.69%. Browse 116 ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... effective tool for both the identification of known species and ... barcoding is based on the fact that just a small ... is less variation between the individuals of one species than ... barcode sequences one can establish whether these belong to one ...
... proposal to discontinue protection for the gray wolf across ... endangering other species, researchers say. As written, scientists ... the U.S. Fish and Wildlife Service (FWS) to declare ... exists on the land the exact opposite of ...
... European Caucasian patients with sporadic amyotrophic lateral sclerosis ... Tau (MAPT) gene was significantly associated with sporadic ... a different population, Daojun Hong and colleagues from ... MAPT gene with sporadic amyotrophic lateral sclerosis in ...
Cached Biology News:Museum bird DNA 'ready for use' in Naturalis Biodiversity Center 2Plan to delist gray wolf endangers other threatened species, researchers find 2Plan to delist gray wolf endangers other threatened species, researchers find 3
Anti-MT3-MMP Membrane-Type Metalloproteinase-3; propeptide domain; rabbit host...
Rabbit polyclonal to Methionine Aminopeptidase 2 ( Abpromise for all tested applications). entrezGeneID: 10988 SwissProtID: P50579...
Mouse monoclonal [TU-20] to beta III Tubulin (FITC) ( Abpromise for all tested applications). entrezGeneID: 10381 SwissProtID: Q13509...
Chlamydia pneumoniae (TWAR)...
Biology Products: